2014年3月20日訊 /生物谷BIOON/ --私募投資公司GTCR公司最近宣布公司已經與另外兩家風投公司合作融資3億美元創建Maravai生命技術公司。而在生物技術產業中具有三十年管理經驗的Carl Hull和曾在摩根財團供職的Eric Tardif被將被任命為這家新成立公司的高管。Hull此前曾在專注於女性健康簡冊方法的生物技術公司Gen-Probe公司擔任CEO。去年該公司被Hologic公司以37億美元的價格收購。新成立的Maravai公司業務將主要集中在實驗室服務、體外檢測等領域的業務上，公司將首先通過收購一系列同類公司來增強公司實力和擴大公司規模。
GTCR公司並未透露Maravai公司何時正式掛牌運營，不過公司表示一系列籌備工作正在有條不紊地進行。（生物谷Bioon.com）
詳細英文報導：
Private equity outfit GTCR has recruited two industry veterans and put up $300 million to create Maravai Life Sciences, a buyout-focused firm out to make some deals.
Fresh off closing a $3.3 billion oversubscribed fund, GTCR is launching Maravai alongside Carl Hull, a former med tech CEO with 30 years experience in the industry, and Eric Tardif, an ex-Morgan Stanley exec with experience managing diagnostics M&A. The plan is to buy companies primarily in in vitro testing, lab services and life sciences tools, accelerating their growth through investment and bolt-on deals, according to Maravai.
And for Hull, boosting the value of diagnostics companies is hardly a new endeavor. Most recently, he served as the CEO of Gen-Probe, a women's health-focused testing outfit bought by Hologic ($HOLX) for $3.7 billion last year. Before that, he had leadership roles at Ventana Medical Systems, which Roche ($RHHBY) acquired for $3.4 billion, and Applied Biosystems, the company that became Life Technologies through a $6.7 billion merger.
Now he's out to do the same for some smaller operations. Maravai is on the hunt for revenue-generating companies with operating earnings above $15 million, looking to shepherd their growth and create value. GTCR, now on its 11th fund, has quite an established track record of doing just that, Hull said, dovetailing with his expertise across the life sciences spectrum.
"From my perspective, I've had the opportunity to work in the traditional diagnostics business, in life sciences and at research companies," Hull told FierceBiotech. "It's that range of experience that makes me comfortable with this kind of opportunity to assess and look at technologies and businesses across the industry."
Maravai doesn't have a set timeline for lining up deals, but Hull said the group is already in the thick of vetting targets and working through due diligences.
"We're going to be patient and disciplined," he said. "We're really going to look for the right opportunities and make intelligent decisions to build a compelling company, but a compelling company that has a long-term focus."